SIX Group offers to buy Spanish stock exchange company BME for €2.84bn
SIX Group, a Swiss financial services company, has proposed to acquire 100% of Spanish stock exchange company Bolsas y Mercados Españoles (BME) for €34 per ... Read More
Dicerna, Roche strike $1.67bn deal for hepatitis B virus therapies
Dicerna Pharmaceuticals has secured a research collaboration and licensing deal worth up to $1.67 billion with Roche to develop new drugs for chronic hepatitis B ... Read More
Galderma launches phase 3 atopic dermatitis trial for nemolizumab
Galderma, a Nestle-owned Swiss pharma company, said that it has enrolled the first patients in a phase 3 clinical study evaluating nemolizumab for the treatment ... Read More
Aryzta to sell 43% stake in French frozen food producer Picard
Swiss food company Aryzta has been given a binding offer from Tunisian investment group Invest Group Zouari (IGZ) to sell the majority of its stake ... Read More
Temenos to acquire Kony to advance digital front office product Temenos Infinity
Temenos acquisition of Kony : Temenos, a Swiss banking software company, has agreed to acquire Kony, a US-based digital banking SaaS company, for an enterprise ... Read More
Boehringer Ingelheim acquires Swiss biotech company AMAL Therapeutics
Boehringer Ingelheim acquisition of AMAL Therapeutics : German pharma company Boehringer Ingelheim has acquired Swiss biotech company AMAL Therapeutics for up to EUR325 million, as ... Read More
Pfizer wraps up $810m acquisition of Swiss biotech company Therachon
Pfizer acquisition of Therachon : US pharma giant Pfizer has completed its previously announced acquisition of Swiss biotech company Therachon, which is focused on rare ... Read More
Medical Properties Trust acquires stake in Switzertland’s Infracore
US-based real estate investment trust Medical Properties Trust (MPT) has acquired a 46% stake in Swiss healthcare real estate company Infracore from its previous majority ... Read More
Swiss pharma Orphan Technologies launches phase 1/2 clinical trial for OT-58 in classical homocystinuria
Orphan Technologies, a Swiss pharmaceutical company, has officially dosed the first patients in its groundbreaking phase 1/2 clinical trial, CBS-HCY-01, for OT-58, a modified recombinant ... Read More
Novartis completes $2.1bn acquisition of Endocyte to boost cancer treatment capabilities
Swiss pharmaceutical giant Novartis has officially closed its $2.1 billion acquisition of US-based biopharma company Endocyte, solidifying its position as a leader in radiopharmaceuticals for ... Read More